Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer
Clinical Nutrition, 06/04/2012Miyata H et al.
Compared with PN support, Enteral nutrition (EN) support during neoadjuvant chemotherapy reduced the incidence of chemotherapy–related hematological toxicities in patients with esophageal cancers.
Ninety-one patients who received neoadjuvant chemotherapy (5-fluorouracil, cisplatin and adriamycin) for esophageal cancer were enrolled to receive either EN (n=47) or PN (n=44) at random.
The primary endpoint was the incidence of chemotherapy-related toxicities during chemotherapy.
Total and dietary intake calories during chemotherapy were equal in the two groups.
There were no significant differences in serum albumin level and body weight change after chemotherapy between the two groups.
There was no significant difference in tumor response to chemotherapy between the two groups (EN: 51%, PN: 55%, p = 0.886).
Leukopenia and neutropenia of grade 3 or 4, defined according to the Common Toxicities Criteria of the National Cancer Institute, were significantly less frequent in the EN group than PN group (leukopenia: 17% vs 41%, p = 0.011, neutropenia: 36% vs 66%, p = 0.005).
Lymphopenia and thrombocytopenia tended to be less frequent in the EN group, albeit insignificantly.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.